{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Siponimod", "query": { "intervention": "Siponimod" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 24, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Siponimod&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T03:38:54.197Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06588387", "title": "A Real-world Study to Assess the Use of Siponimod in Spain to Treat Patients With Secondary Progressive Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Secondary Progressive Multiple Sclerosis" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 210, "start_date": "2022-11-03", "completion_date": "2023-09-08", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-09-03T03:38:54.197Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06588387" }, { "nct_id": "NCT01801917", "title": "Efficacy and Tolerability of BAF312 in Patients With Polymyositis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Polymyositis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "BAF312", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 14, "start_date": "2013-04-24", "completion_date": "2016-08-05", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-09-03T03:38:54.197Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01801917" }, { "nct_id": "NCT00879658", "title": "Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsing-remitting Multiple Sclerosis" ], "interventions": [ { "name": "BAF312", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 297, "start_date": "2009-03-30", "completion_date": "2011-05-04", "has_results": true, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-09-03T03:38:54.197Z", "location_count": 16, "location_summary": "Cullman, Alabama • San Francisco, California • Centennial, Colorado + 13 more", "locations": [ { "city": "Cullman", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Pompano Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00879658" }, { "nct_id": "NCT05688436", "title": "A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Diroximel Fumarate", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "BIOLOGICAL" }, { "name": "Fingolimod", "type": "DRUG" }, { "name": "Glatiramer acetate", "type": "DRUG" }, { "name": "Interferon beta", "type": "BIOLOGICAL" }, { "name": "Natalizumab", "type": "BIOLOGICAL" }, { "name": "Ocrelizumab", "type": "BIOLOGICAL" }, { "name": "Ofatumumab", "type": "BIOLOGICAL" }, { "name": "Ozanimod", "type": "DRUG" }, { "name": "Peginterferon beta-1a", "type": "BIOLOGICAL" }, { "name": "Ponesimod", "type": "DRUG" }, { "name": "Siponimod", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "FEMALE", "summary": "18 Years to 49 Years · Female only" }, "enrollment_count": 1178, "start_date": "2021-09-24", "completion_date": "2031-01-17", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-03T03:38:54.197Z", "location_count": 1, "location_summary": "Eden Prairie, Minnesota", "locations": [ { "city": "Eden Prairie", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05688436" }, { "nct_id": "NCT04925557", "title": "Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Secondary-progressive Multiple Sclerosis" ], "interventions": [ { "name": "Mayzent", "type": "DRUG" }, { "name": "Ocrevus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "State University of New York at Buffalo", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 8, "start_date": "2021-11-13", "completion_date": "2023-08-05", "has_results": true, "last_update_posted_date": "2025-05-13", "last_synced_at": "2026-09-03T03:38:54.197Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04925557" }, { "nct_id": "NCT03623243", "title": "Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Sclerosis", "Relapsing Multiple Sclerosis", "Advancing Multiple Sclerosis" ], "interventions": [ { "name": "Siponimod", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 185, "start_date": "2019-02-14", "completion_date": "2022-07-06", "has_results": true, "last_update_posted_date": "2024-06-20", "last_synced_at": "2026-09-03T03:38:54.197Z", "location_count": 54, "location_summary": "Birmingham, Alabama • Cullman, Alabama • Homewood, Alabama + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Cullman", "state": "Alabama" }, { "city": "Homewood", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03623243" }, { "nct_id": "NCT06639282", "title": "Repurposing Siponimod for Alzheimer's Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Alzheimer Disease", "Mild Alzheimer Disease", "MCI With Increased Risk for Alzheimer Disease", "Cognitive Impairment, Mild" ], "interventions": [ { "name": "Siponimod", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Joseph's Hospital and Medical Center, Phoenix", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "50 Years to 85 Years" }, "enrollment_count": 105, "start_date": "2025-08-26", "completion_date": "2029-10", "has_results": false, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-09-03T03:38:54.197Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06639282" }, { "nct_id": "NCT07168694", "title": "A Real-world Study About the Impact of Siponimod Treatment on Secondary Progressive Multiple Sclerosis Patients in Russia", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Secondary Progressive Multiple Sclerosis" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 606, "start_date": "2024-04-16", "completion_date": "2024-09-26", "has_results": false, "last_update_posted_date": "2025-09-11", "last_synced_at": "2026-09-03T03:38:54.197Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07168694" }, { "nct_id": "NCT06459232", "title": "Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying Therapies", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 143, "start_date": "2020-11-19", "completion_date": "2021-12-17", "has_results": false, "last_update_posted_date": "2024-06-14", "last_synced_at": "2026-09-03T03:38:54.197Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06459232" }, { "nct_id": "NCT06395909", "title": "A Study to Assess the Effectiveness and Safety of Mayzent in Chinese Patients With Relapsing Forms of Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Relapsing Multiple Sclerosis", "Clinically Isolated Syndrome", "Relapsing Remitting Multiple Sclerosis", "Secondary Progressive Multiple Sclerosis" ], "interventions": [], "intervention_types": [], "sponsor": "Novartis", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 113, "start_date": "2023-04-23", "completion_date": "2023-08-31", "has_results": false, "last_update_posted_date": "2024-05-02", "last_synced_at": "2026-09-03T03:38:54.197Z", "location_count": 1, "location_summary": "East Hanover, New Jersey", "locations": [ { "city": "East Hanover", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06395909" } ] }